



4510 IE

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵: A61K 31/19, 31/16 C07C 235/78	A1	(11) International Publication Number: WO 93/07865 (43) International Publication Date: 29 April 1993 (29.04.93)
(21) International Application Number: PCT/US92/08742 (22) International Filing Date: 12 October 1992 (12.10.92) (30) Priority data: 777,855 16 October 1991 (16.10.91) US 951,547 1 October 1992 (01.10.92) US (71) Applicant: THE PROCTER & GAMBLE COMPANY [US/US]; One Procter & Gamble Plaza, Cincinnati, OH 45202 (US). (72) Inventors: DOBSON, Roy, Lee, Martin ; 7148 St. Alban's Way, Hamilton, OH 45011 (US). WEHMEYER, Ken- neth, Robert ; 3625 Stettinius, Cincinnati, OH 45208 (US). SIRKO, Steven, Peter ; 30 Lamplighter Court, Fairfield, OH 45014 (US). FLOYD, Benjamin, Franklin ; 15 Annadale Lane, Cincinnati, OH 45246 (US).	(74) Agents: REED, T., David et al.; The Procter & Gamble Company, 5299 Spring Grove Avenue, Cincinnati, OH 45202 (US). (81) Designated States: AU, BB, BG, BR, CA, CS, FI, HU, JP, KP, KR, LK, MG, MN, MW, NO, PL, RO, RU, SD, Eu- ropean patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG). Published <i>With international search report.</i>	

REPLACED SHEETS SG

- ☒ Description : paged ...1... to paged ...10...
☒ Claim(s) : paged ...11... to paged ...12...
☐ Drawing(s) : paged to paged
☒ Abstract : paged ...13... to paged ...14...

DATE OF RECEIPT

(54) Title: DI-TERT-BUTYLPHENOL COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS**(57) Abstract**

The subject invention involves compositions comprising 4-(3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)-4-oxobutanamide, or 4-(3,5-bis-(1,1-dimethylethyl)-4-hydroxyphenyl)-4-oxobutanoic acid and pharmaceutically-acceptable salts thereof, and a pharmaceutically-acceptable carrier. The subject invention also involves methods for treating diseases characterized by inflammation and/or pain, such as rheumatoid arthritis and osteoarthritis, in humans or lower animals by administration of a safe and effective amount of this compound to the human or lower animal in need of such treatment.

This Sheet Has Been Replaced

